FDA to review generic blood-pressure med

Share this article:

FDA plans to study generic copies of AstraZeneca's extended-release blood pressure medication Toprol XL (metroprolol succinate), amid 3,424 adverse-incident reports made against the drugs.

Those AE reports cite “a lack of effectiveness and troublesome side effects,” reports Bloomberg, which analyzed them.

According to the news service, FDA will assess whether the copies are chemically the same as the original, as noted in a funding request made by the agency.

The generic copies in question are manufactured by Wockhardt Ltd. and Dr. Reddy's Laboratories, both of which are based in India, and by US-based Mylan and Actavis.

The effort to evaluate metoprolol succinate broadens on a $20-million FDA testing program begun in September, Bloomberg points out, and follows criticism of the agency's handling of generics made overseas and distributed domestically.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.